Cargando…
“Endothelial Antibody Factory” at the Blood Brain Barrier: Novel Approach to Therapy of Neurodegenerative Diseases
The failures of anti-β-amyloid immunotherapies suggested that the very low fraction of injected antibodies reaching the brain parenchyma due to the filtering effect of the BBB may be a reason for the lack of therapeutic effect. However, there is no treatment, as yet, for the amyotrophic lateral scle...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320725/ https://www.ncbi.nlm.nih.gov/pubmed/35890313 http://dx.doi.org/10.3390/pharmaceutics14071418 |
_version_ | 1784755861618425856 |
---|---|
author | Thinard, Reynald Farkas, Attila E. Halasa, Marta Chevalier, Melanie Brodaczewska, Klaudia Majewska, Aleksandra Zdanowski, Robert Paprocka, Maria Rossowska, Joanna Duc, Lam Tri Greferath, Ruth Krizbai, Istvan Van Leuven, Fred Kieda, Claudine Nicolau, Claude |
author_facet | Thinard, Reynald Farkas, Attila E. Halasa, Marta Chevalier, Melanie Brodaczewska, Klaudia Majewska, Aleksandra Zdanowski, Robert Paprocka, Maria Rossowska, Joanna Duc, Lam Tri Greferath, Ruth Krizbai, Istvan Van Leuven, Fred Kieda, Claudine Nicolau, Claude |
author_sort | Thinard, Reynald |
collection | PubMed |
description | The failures of anti-β-amyloid immunotherapies suggested that the very low fraction of injected antibodies reaching the brain parenchyma due to the filtering effect of the BBB may be a reason for the lack of therapeutic effect. However, there is no treatment, as yet, for the amyotrophic lateral sclerosis (ALS) despite substantial evidence existing of the involvement of TDP-43 protein in the evolution of ALS. To circumvent this filtering effect, we have developed a novel approach to facilitate the penetration of antibody fragments (Fabs) into the brain parenchyma. Leveraging the homing properties of endothelial progenitor cells (EPCs), we transfected, ex vivo, such cells with vectors encoding anti-β-amyloid and anti-TDP43 Fabs turning them into an “antibody fragment factory”. When injected these cells integrate into the BBB, where they secrete anti-TDP43 Fabs. The results showed the formation of tight junctions between the injected engineered EPCs and the unlabeled resident endothelial cells. When the EPCs were further modified to express the anti-TDP43 Fab, we could observe integration of these cells into the vasculature and the secretion of Fabs. Results confirm that production and secretion of Fabs at the BBB level leads to their migration to the brain parenchyma where they might exert a therapeutic effect. |
format | Online Article Text |
id | pubmed-9320725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93207252022-07-27 “Endothelial Antibody Factory” at the Blood Brain Barrier: Novel Approach to Therapy of Neurodegenerative Diseases Thinard, Reynald Farkas, Attila E. Halasa, Marta Chevalier, Melanie Brodaczewska, Klaudia Majewska, Aleksandra Zdanowski, Robert Paprocka, Maria Rossowska, Joanna Duc, Lam Tri Greferath, Ruth Krizbai, Istvan Van Leuven, Fred Kieda, Claudine Nicolau, Claude Pharmaceutics Article The failures of anti-β-amyloid immunotherapies suggested that the very low fraction of injected antibodies reaching the brain parenchyma due to the filtering effect of the BBB may be a reason for the lack of therapeutic effect. However, there is no treatment, as yet, for the amyotrophic lateral sclerosis (ALS) despite substantial evidence existing of the involvement of TDP-43 protein in the evolution of ALS. To circumvent this filtering effect, we have developed a novel approach to facilitate the penetration of antibody fragments (Fabs) into the brain parenchyma. Leveraging the homing properties of endothelial progenitor cells (EPCs), we transfected, ex vivo, such cells with vectors encoding anti-β-amyloid and anti-TDP43 Fabs turning them into an “antibody fragment factory”. When injected these cells integrate into the BBB, where they secrete anti-TDP43 Fabs. The results showed the formation of tight junctions between the injected engineered EPCs and the unlabeled resident endothelial cells. When the EPCs were further modified to express the anti-TDP43 Fab, we could observe integration of these cells into the vasculature and the secretion of Fabs. Results confirm that production and secretion of Fabs at the BBB level leads to their migration to the brain parenchyma where they might exert a therapeutic effect. MDPI 2022-07-06 /pmc/articles/PMC9320725/ /pubmed/35890313 http://dx.doi.org/10.3390/pharmaceutics14071418 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Thinard, Reynald Farkas, Attila E. Halasa, Marta Chevalier, Melanie Brodaczewska, Klaudia Majewska, Aleksandra Zdanowski, Robert Paprocka, Maria Rossowska, Joanna Duc, Lam Tri Greferath, Ruth Krizbai, Istvan Van Leuven, Fred Kieda, Claudine Nicolau, Claude “Endothelial Antibody Factory” at the Blood Brain Barrier: Novel Approach to Therapy of Neurodegenerative Diseases |
title | “Endothelial Antibody Factory” at the Blood Brain Barrier: Novel Approach to Therapy of Neurodegenerative Diseases |
title_full | “Endothelial Antibody Factory” at the Blood Brain Barrier: Novel Approach to Therapy of Neurodegenerative Diseases |
title_fullStr | “Endothelial Antibody Factory” at the Blood Brain Barrier: Novel Approach to Therapy of Neurodegenerative Diseases |
title_full_unstemmed | “Endothelial Antibody Factory” at the Blood Brain Barrier: Novel Approach to Therapy of Neurodegenerative Diseases |
title_short | “Endothelial Antibody Factory” at the Blood Brain Barrier: Novel Approach to Therapy of Neurodegenerative Diseases |
title_sort | “endothelial antibody factory” at the blood brain barrier: novel approach to therapy of neurodegenerative diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320725/ https://www.ncbi.nlm.nih.gov/pubmed/35890313 http://dx.doi.org/10.3390/pharmaceutics14071418 |
work_keys_str_mv | AT thinardreynald endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT farkasattilae endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT halasamarta endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT chevaliermelanie endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT brodaczewskaklaudia endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT majewskaaleksandra endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT zdanowskirobert endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT paprockamaria endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT rossowskajoanna endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT duclamtri endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT greferathruth endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT krizbaiistvan endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT vanleuvenfred endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT kiedaclaudine endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases AT nicolauclaude endothelialantibodyfactoryatthebloodbrainbarriernovelapproachtotherapyofneurodegenerativediseases |